In April, Nucleix secured $55 million in funding to develop its Lung EpiCheck platform for earlier detection of lung cancer. Image courtesy of Nucleix.

In April, Nucleix secured $55 million in funding to develop its Lung EpiCheck platform for earlier detection of lung cancer. Image courtesy of Nucleix.

Nucleix, a liquid biopsy company that is innovating cancer treatment with earlier disease detection, secured $55 million to finance the development of its lead product, Lung EpiCheck. ...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99